TY - CHAP M1 - Book, Section TI - Lower Extremity Peripheral Arterial Disease A1 - Ramana, Ravi K. A1 - Lewis, Bruce E. A1 - Dieter, Robert S. A2 - Dieter, Robert S. A2 - Dieter, Raymond A. A2 - Dieter, Raymond A. PY - 2009 T2 - Peripheral Arterial Disease AB - Lower extremity peripheral arterial disease (LEPAD) is a major cause of poor quality of life, disability, and significant morbidity and mortality in the United States.1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17 In this chapter, LEPAD is used to refer to any arterial disease affecting the lower extremity, including occlusive, aneursymal, and vasculitic disease states. Even when asymptomatic, LEPAD has been shown to decrease mobility and bone mineral density8,9,12,18; leads to foot ulcers and amputations8,19; and be a strong predictor of subsequent cardiovascular (CV) disease, nonfatal CV events (e.g., myocardial infarction and stroke), and mortality.6,10,20 Standard therapy for LEPAD should include antiplatelet therapy and be directed at control of risk factors including smoking cessation, lipid management, strict diabetic therapy, and control of blood pressure21 in attempts to stop progression of the systemic atherosclerotic process. Current therapy on symptomatic disease includes exercise therapy, antiplatelet medications, and a variety of percutaneous interventional and surgical procedures. Therefore, early diagnosis and appropriate therapy for LEPAD can significant improve quality of life and decrease significant morbidity and CV mortality. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesscardiology.mhmedical.com/content.aspx?aid=1127168379 ER -